Compositions and methods for reducing reperfusion injury
A pharmaceutical composition comprising a lipid component, an amphiphilic emulsifier, a polar liquid carrier, and one or more electrolytes, where the amphiphilic emulsifier forms lipid carrying micelles having a lipophilic core comprising the lipid component in the polar liquid carrier, and/or liposomes organized as a lipid bilayer and/or other particle configurations. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating ischemic conditions with reduced reperfusion injury.
1. A method for reducing reperfusion injury in the lung tissue in a subject treated for ischemia, comprising:
administering to a subject in need of treatment for ischemia, an effective amount of a pharmaceutical composition comprising:
a lipid component in an amount of 0-35% (w/v);
an amphiphilic emulsifier in an amount of 6%-60% (w/v);
a polar liquid carrier; and
one or more electrolytes,
wherein the amphiphilic emulsifier forms lipid carrying micelles having a lipophilic core comprising the lipid component in the polar liquid carrier,
wherein the micelles have diameters between 30 nm and 160 nm, and
wherein the composition reduces reperfusion injury in the lung tissue.
2. The method of claim 1 , wherein the pharmaceutical composition further comprises liposomes with diameters of 30 nm or smaller.
3. The method of claim 1 , wherein the pharmaceutical composition further comprises liposomes with diameters of 5-20 nm.
4. The method of claim 1 , wherein the pharmaceutical composition comprises a mixture of micelles with diameters of 40-100 nm and liposomes with diameters of 10-20 nm.
5. The method of claim 1 , wherein the pharmaceutical composition comprises a mixture of micelles and liposomes, wherein the micelles and liposomes have diameters in the range of 1-140 nm.
6. The method of claim 5 , wherein the micelles and liposomes have diameters in the range of 5-120 nm.
7. The method of claim 5 , wherein an average diameter of particles consisting of micelles and liposomes is in the range of 10-25 nm.
8. The method of claim 1 , wherein the pharmaceutical composition comprises a lipid component in an amount of 15-35% (w/v) and an amphiphilic emulsifier in an amount of 6%-18% (w/v).
9. The method of claim 8 , wherein the lipid component is soy bean oil and the amphiphilic emulsifier is egg lecithin.
10. The method of claim 1 , wherein the pharmaceutical composition comprises a mixture of liposomes with diameters in the range of 1-20 nm and micelles with diameters in the range of 70-110 nm.
11. The method of claim 1 , wherein the pharmaceutical composition comprises a mixture of liposomes with diameters in the range of 5-15 nm and micelles with diameters in the range of 90-100 nm.
12. The method of claim 1 , wherein the pharmaceutical composition further comprises histidine at a final concentration of 0.001 μM-100 mM.
13. The method of claim 12 , wherein the pharmaceutical composition further comprises histidine at a final concentration of 1 μM-10 mM.
14. A composition for reducing reperfusion injury in the lung tissue in a subject treated for ischemia, comprising:
a lipid component in an amount of 0-35% (w/v);
an amphiphilic emulsifier in an amount of 6%-60% (w/v);
a polar liquid carrier;
one or more electrolytes, and
0.001 μM-100 mM histidine
wherein the amphiphilic emulsifier forms liposomes having a hydrophilic core and micelles having a lipophilic core, wherein the liposomes have diameters in the range of 1-30 nm and wherein the micelles have diameters between 30 nm and 160 nm, and wherein the composition reduces reperfusion injury in the lung tissue.
15. The composition of claim 14 , wherein the liposomes have diameters in the range of 5-20 nm.
16. The composition of claim 14 , wherein the micelles have diameters in the range of 40-120 nm.
17. The composition of claim 14 , wherein the pharmaceutical composition comprises a mixture of micelles with diameters of 40-100 nm and liposomes with diameters of 5-25 nm.
18. The composition of claim 14 , wherein the composition comprises a lipid component in an amount of 15-35% (w/v) and an amphiphilic emulsifier in an amount of 6%-18% (w/v).
19. The composition of claim 18 , wherein the lipid component is soy bean oil and the amphiphilic emulsifier is egg lecithin.
20. The composition of claim 14 , wherein the subject is treated to reduce reperfusion injury in the lung, small and large intestine and kidney.
21. The method of claim 1 , wherein the pharmaceutical composition has an average particle size of 16.88 nm.
22. The composition of claim 14 , wherein the pharmaceutical composition comprises an average particle size of 16.88 nm.
23. The method of claim 1 , wherein the pharmaceutical composition further comprises liposomes with an average diameter in the range of 1-5 nm.
24. The composition of claim 14 , wherein the pharmaceutical composition further comprises liposomes with an average diameter of 1-5 nm.
25. The method of claim 1 , wherein the pharmaceutical composition further comprises liposomes with an average diameter in the range of 1-10 nm.
26. The composition of claim 14 , wherein the pharmaceutical composition further comprises liposomes with an average diameter of 1-10 nm.
27. The method of claim 1 , wherein the pharmaceutical composition further comprises liposomes with an average diameter in the range of 1-15 nm.
28. The composition of claim 14 , wherein the pharmaceutical composition further comprises liposomes with an average diameter of 1-15 nm.